Neoplasms, Plasma Cell: all 2,314 studies
Page 18 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma PatientsWithdrawnNCT01269203Phase 2
- Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.CompletedNCT01268774
- A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT01266811Phase 3
- Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic TransplantCompletedNCT01264315Phase 2
- Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 StudyStatus unknownNCT01255527Phase 1/2
- Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple MyelomaCompletedNCT01255514Phase 2
- RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT01251172Phase 2
- Efficacy Study of PAD and TAD in Newly Diagnosed Multiple MyelomaStatus unknownNCT01249690Phase 4
- A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01248923Phase 1
- Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple MyelomaCompletedNCT01242930Phase 2
- A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any ProcedureCompletedNCT01241396
- Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose DexamethasoneCompletedNCT01237249Phase 2
- IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor EverolimusWithdrawnNCT01234974Phase 2
- Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple MyelomaCompletedNCT01234129
- Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple MyelomaCompletedNCT01233895Phase 1
- PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With MyelomaCompletedNCT01220375Phase 2
- A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple MyelomaCompletedNCT01219010Phase 1
- Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second RelapseCompletedNCT01217203Phase 1
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01208766Phase 3
- Frontline Therapy in de Novo Multiple Myeloma Patients Under 65CompletedNCT01206205Phase 2
- Study of CX-4945 in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT01199718Phase 1
- Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 YearsCompletedNCT01191060Phase 3
- Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus PrednisoneCompletedNCT01190787Phase 2
- Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)CompletedNCT01186224Not applicable
- Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple MyelomaCompletedNCT01183949Phase 1/2
- Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell TransplantationTerminatedNCT01182233Phase 1
- Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersActive, not recruitingNCT01177527
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression FracturesWithdrawnNCT01175278Not applicable
- The Pathophysiology of Bortezomib Induced Peripheral NeuropathyStatus unknownNCT01171443
- "WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free SurvivalCompletedNCT01171430Not applicable
- Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01168804Phase 2
- Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to LenalidomideCompletedNCT01166113Phase 1/2
- Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic CancerCompletedNCT01164709Phase 1
- Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma PatientsCompletedNCT01160107Phase 2
- Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple MyelomaCompletedNCT01148108Phase 2
- A Study of AT9283 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01145989Phase 2
- VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)Status unknownNCT01134484Phase 3
- Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving ChemotherapyCompletedNCT01132833
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
- A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple MyelomaCompletedNCT01122875Phase 1
- Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma PatientsTerminatedNCT01121120Phase 2
- Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom MacroglobulinemiaCompletedNCT01118689Phase 1
- Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma PatientsTerminatedNCT01116128Phase 2
- Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MMCompletedNCT01114282Phase 1
- Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)Status unknownNCT01114048Phase 2
- Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)TerminatedNCT01109407
- Exploratory Study on POL6326 in Stem Cell MobilizationCompletedNCT01105403Phase 2
- A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple MyelomaTerminatedNCT01101594Phase 1/2
- Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWithdrawnNCT01101412Phase 1/2
- Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma PatientsCompletedNCT01093196Phase 3
- Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01091831Phase 3
- Combination of Lenalidomide and Dexamethasone in Treatment of Multiple MyelomaCompletedNCT01090089Phase 3
- Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical RelapseCompletedNCT01087008Phase 4
- Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal FailureCompletedNCT01084837Phase 2
- Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.TerminatedNCT01079429
- Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell TransplantTerminatedNCT01077440
- Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT01074060Phase 1
- Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.CompletedNCT01070862Phase 3
- Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma PatientsCompletedNCT01063179Phase 3
- Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early BortezomibCompletedNCT01060202
- Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal TranslocationCompletedNCT01058434Phase 2
- S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT01055301Phase 2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple MyelomaCompletedNCT01045681Phase 2
- Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple MyelomaCompletedNCT01042704Phase 1
- Expanded Natural Killer (NK) Cells for Multiple Myeloma StudyCompletedNCT01040026Phase 1/2
- TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple MyelomaCompletedNCT01039025Phase 2
- A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01038388Phase 1
- A Retreatment Study With Bortezomib for Multiple MyelomaCompletedNCT01030302
- Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.CompletedNCT01026701
- A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple MyelomaCompletedNCT01025206Phase 1
- Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent TherapyTerminatedNCT01023880Phase 1/2
- Quality of Life in Multiple Myeloma Patients Treated With BortezomibCompletedNCT01021592
- Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01019174Phase 1/2
- Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma SubjectsTerminatedNCT01018927
- Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma PatientsCompletedNCT01010880Phase 1/2
- Third-line Therapy of Multiple Myeloma a Prospective Phase I /II TrialStatus unknownNCT01010243Phase 1/2
- Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the SpineCompletedNCT01006070
- Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT01002703Phase 1/2
- Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma PatientsTerminatedNCT01002248Phase 3
- UARK 2009-32 Compassionate Use Study of CarfilzomibNo longer availableNCT00999414
- Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple MyelomaStatus unknownNCT00998270Phase 2/3
- Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple MyelomaCompletedNCT00996957Phase 1
- Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body IrradiationTerminatedNCT00996359Phase 1
- Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT00995059Phase 1/2
- Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With DapsoneCompletedNCT00993694
- IMGN901 in Combination With Lenalidomide and DexamethasoneCompletedNCT00991562Phase 1
- Dendritic Cells(DC)-Based Id Vaccination in Stage-I MyelomaCompletedNCT00988312Phase 1
- Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma PatientsTerminatedNCT00984828Phase 2/3
- Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaCompletedNCT00972712Phase 1
- Agaricus Blazei Murill in Patients With Multiple MyelomaCompletedNCT00970021Phase 2
- Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell GraftsWithdrawnNCT00968396Phase 2
- Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and MyelomaCompletedNCT00965224Phase 2
- Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell TransplantCompletedNCT00964821
- Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00962507Phase 1
- RMPT for Relapsed/Refractory Multiple MyelomaCompletedNCT00961467Phase 2
- Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSFCompletedNCT00952237Phase 1
- Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy VolunteersTerminatedNCT00952185Not applicable
- A Standardized Nursing Intervention Protocol for HCT PatientsCompletedNCT00951626Not applicable